Editing Kidney Cancer: Diagnosis and Evaluation (section)

===== Indications =====

====== CUA ======
* '''[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932428/ 2022 CUA Guidelines on Management of Small Renal Masses]'''
** '''<span style="color:#ff0000">Should be offered when the result of the biopsy will influence management'''

====== AUA ======

* [https://pubmed.ncbi.nlm.nih.gov/28479239/ '''2021 AUA Guidelines on Renal Mass and Localized Renal Cancer''']
** Currently has an adjunctive role in the diagnosis and risk stratification of patients with renal masses suspicious for RCC
** '''<span style="color:#ff0000">Consider biopsy when a mass is suspected to be hematologic, metastatic, inflammatory, or infectious.</span>'''
*** See [[Management of Localized and Locally Advanced Disease|Kidney Cancer: Non-Renal Cell Carcinoma Renal Malignancies Chapter Notes]]
*** If metastatic cancer is confirmed, systemic treatment is typically prioritized.
*** Index of suspicion for a non-neoplastic process, such as renal sarcoidosis, abscess, or focal pyelonephritis, should be increased in patients presenting with signs and symptoms consistent with an infectious or inflammatory condition or those with a prior history of recurrent infections or autoimmune disease
** '''<span style="color:#ff0000">Should be obtained if it will influence management</span>'''
***'''<span style="color:#ff0000">NOT required for (2):</span>'''
***#'''<span style="color:#ff0000">Young or healthy patients who are unwilling to accept the uncertainties associated with RMB</span>'''
***#'''<span style="color:#ff0000">Older or frail patients who will be managed conservatively independent of RMB findings</span>'''